Rates within 21 days of vaccination extremely rare and similar to those with influenza and Tdap vaccines<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, April 17, 2023 (HealthDay News) — COVID-19 vaccines do not increase the risk for new-onset retinal vascular occlusion (RVO), according to a study published online April 13 in JAMA Ophthalmology<\/em>.<\/p>\n Ian Dorney, from the Case Western Reserve University School of Medicine in Cleveland, and colleagues compared the incidence of new acute RVO diagnosis after the mRNA COVID-19 vaccine versus the influenza and tetanus, diphtheria, pertussis (Tdap) vaccines. The analysis included electronic health record data from 103 million patients.<\/p>\n The researchers found that of 3.1 million patients who received the mRNA COVID-19 vaccine, 104 (0.003 percent) had a new diagnosis of RVO within 21 days of vaccination. In a propensity score-matched analysis, there was no significant difference noted in the risk for new RVO diagnosis after the first dose of COVID-19 vaccination versus after the influenza (relative risk, 0.74; 95 percent confidence interval, 0.54 to 1.01) or Tdap (relative risk, 0.78; 95 percent confidence interval, 0.44 to 1.38) vaccinations. However, risk was greater after the second dose of the COVID-19 vaccination (relative risk, 2.25; 95 percent confidence interval, 1.33 to 3.81).<\/p>\n “The findings of this study suggest that RVO diagnosed acutely after mRNA COVID-19 vaccination occurs extremely rarely at rates similar to those of two different historically used vaccinations, the influenza and Tdap vaccines,” the authors write.<\/p>\n Two study authors disclosed financial ties to the biotechnology and pharmaceutical industries.<\/p>\n Abstract\/Full Text<\/a><\/p>\n